Distribution of 76Br-labeled antisense oligonucleotides of different length determined ex vivo in rats

European Journal of Pharmaceutical Sciences

Volumn 10, Issue 3, 2000, Pages 179-186

  Wu, Feng ^a,b   Yngve, Ulrika ^a   Hedberg, Elisabeth ^a   Honda, Michinari ^a   Lu, Li ^a   Eriksson, Barbro ^b   Watanabe, Yasuyoshi ^a,c   Bergström, Mats ^a   Långström, Bengt ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Osaka Prefecture University   (Japan)

Author keywords

76Br; Antisense oligonucleotides; Autoradiography; Chromogranin A; Distribution in vivo; Positron emission tomography (PET)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BROMINE; BROMINE 76; CETYLPYRIDINIUM SALT; CHROMOGRANIN A; DNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN; RNA; UNCLASSIFIED DRUG; CHROMOGRANIN; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DISTRIBUTION; GEL FILTRATION; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY CORTEX; LIVER; MALE; MOLECULAR WEIGHT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SPLEEN; TISSUE DISTRIBUTION; WHOLE BODY AUTORADIOGRAPHY; ANIMAL; AUTORADIOGRAPHY; CELL FRACTIONATION; GEL CHROMATOGRAPHY; METABOLISM; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; AUTORADIOGRAPHY; BROMINE RADIOISOTOPES; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMOGRANIN A; CHROMOGRANINS; DNA; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RNA; STRUCTURE-ACTIVITY RELATIONSHIP; SUBCELLULAR FRACTIONS; TISSUE DISTRIBUTION;

EID: 0033624833     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00067-1     Document Type: Article

References (25)

1. Agrawal S., Iyer R.P. Perspectives in antisense therapeutics. Pharmacol Ther. 76:1997;151-160.
2. Agrawal S., Jiang Z., Zhao Q., Shaw D., Cai Q., Roskey A., Channavajjala L., Saxinger C., Zhang R. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA. 94:1997;2620-2625.
3. Agrawal S., Zhao Q., Jiang Z., Oliver C., Giles H., Heath J., Serota D. Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev. 7:1997;575-584.
4. Amado R.G., Mitsuyasu R.T., Zack J.A. Gene therapy for the treatment of AIDS: animal models and human clinical experience. Front Biosci. 4:1999;D468-475.
5. Bilsky E.J., Bernstein R.N., Hruby V.J., Rothman R.B., Lai J., Porreca F. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated 'knock-down' of opioid receptor in vivo. J. Pharmacol. Exp. Ther. 277:1996;491-501.
6. Carome M.A., Kang Y.H., Bohen E.M., Nicholson D.E., Carr F.E., Kiandoli L.C., Brummel S.E., Yuan C.M. Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo. Nephron. 75:1997;82-87.
7. Crooke S.T., Graham M.J., Zuckerman J.E., Brooks D., Conklin B.S., Cummins L.L., Greig M.J., Guinosso C.J., Kornbrust D., Manoharan M., Sasmor H.M., Schleich T., Tivel K.L., Griffey R.H. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277:1996;923-937.
8. 11C with double-tracer applications. Int. J. Appl. Radiat. Isot. 35:1984;129-134.
9. Edsall S.A., Knapp R.J., Vanderah T.W., Roeske W.R., Consroe P., Yamamura H.I. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. Neuroreport. 7:1996;593-596.
10. Gabay C., Arend W.P. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin. Immunopathol. 20:1998;229-246.
11. Hanecak R., Brown-Driver V., Fox M.C., Azad R.F., Furusako S., Nozaki C., Ford C., Sasmor H., Anderson K.P. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J. Virol. 70:1996;5203-5212.
12. Henry S.P., Templin M.V., Gillett N., Rojko J., Levin A.A. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1 [In Process Citation]. Toxicol. Pathol. 27:1999;95-100.
13. Henry S.P., Zuckerman J.E., Rojko J., Hall W.C., Harman R.J., Kitchen D., Crooke S.T. Toxicological properties of several novel oligonucleotide analogs in mice. Anticancer Drug Des. 12:1997;1-14.
14. Herman J., Adler H., Aguilar-Cordova E., Rojas-Martinez A., Woo S., Timme T., Wheeler T., Thompson T., Scardino P. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther. 10:1999;1239-1249.
15. Kauczor H., Schuler M., Heussel C., von Weymarn A., Bongartz G., Rochlitz C., Huber C., Thelen M. CT-guided intratumoral gene therapy in non-small-cell lung cancer. Eur. Radiol. 9:1999;292-296.
16. Lai J., Crook T.J., Payne A., Lynch R.M., Porreca F. Antisense targeting of delta opioid receptors in NG 108-15 cells: direct correlation between oligodeoxynucleotide uptake and receptor density. J. Pharmacol. Exp. Ther. 281:1997;589-596.
17. Lai J., Riedl M., Stone L.S., Arvidsson U., Bilsky E.J., Wilcox G.L., Elde R., Porreca F. Immunofluorescence analysis of antisense oligodeoxynucleotide-mediated 'knock-down' of the mouse delta opioid receptor in vitro and in vivo. Neurosci. Lett. 213:1996;205-208.
18. Leedman P.J., Stein A.R., Chin W.W. Regulated specific protein binding to a conserved region of the 3′ -untranslated region of thyrotropin beta-subunit mRNA. Mol. Endocrinol. 9:1995;375-387.
19. Sambrook J., Fitsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
20. Sarmiento U.M., Perez J.R., Becker J.M., Narayanan R. In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. 4:1994;99-107.
21. 11C)Ro 15-1788. Nucl. Med. Biol. 24:1997;723-731.
22. Standifer K.M., Jenab S., Su W., Chien C.C., Pan Y.X., Inturrisi C.E., Pasternak G.W. Antisense oligodeoxynucleotides to the cloned delta receptor DOR-1: uptake, stability, and regulation of gene expression. J. Neurochem. 65:1995;1981-1987.
23. Tavitian B., Terrazzino S., Kuhnast B., Marzabal S., Stettler O., Dolle F., Deverre J.R., Jobert A., Hinnen F., Bendriem B., Crouzel C., Giamberardino L.D. In vivo imaging of oligonucleotides with positron emission tomography. Nature Medicine. 4:1998;467-471.
24. 76Br)bromobenzoate and its use in conjugation labelling of macromolecules. Acta Chem. Scand. 53:1999;508-512.
25. Zhao Q., Zhou R., Temsamani J., Zhang Z., Roskey A., Agrawal S. Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice. Antisense Nucleic Acid Drug Dev. 8:1998;451-458.